ArticleRegenerative biomaterials2025
Endocytosis-mediated healing: recombinant human collagen type III chain-induced wound healing for scar-free recovery.
Article in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Skin Relevant Biomaterials from Wound Healing, Medical Aesthetics, Flexible Electronics to Artificial Intelligence and Beyond.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- An injectable photo-crosslinking silk hydrogel system with biphasic release of BTXA and 5-Fu promotes scarless wound healing.RSC advances · 2026Article
- Comparative Evaluation of Single and Combination Pharmacologic and Device-Based Anti-scar Therapies in a Murine Linear Wound Model.Aesthetic plastic surgery · 2026Article
- PLGA/SF/linagliptin wound matrix-induced membrane promotes diabetic wounds healing by inhibiting macrophage pyroptosis.Regenerative biomaterials · 2026Article
- Bioactive granular hydrogels for infection control and immune microenvironment remodeling in wound regeneration.Regenerative biomaterials · 2026Article
- Short-term pretreatment with deferoxamine enhances the in vivo vascularization capacity of nanofat seeded onto dermal substitutes.EXCLI journal · 2026Article
- A recombinant humanized type III collagen coating with anti-inflammatory and endothelialization-promoting effects for left atrial appendage closure devices.Regenerative biomaterials · 2026Article
- An electroactive platform enabled by near-field communication for accelerating infected diabetic wound healing via directional electric field reshaping and immunomodulation.Regenerative biomaterials · 2026Article
- Article
- Research progress on scar-free healing.Annals of medicine · 2025Review
- Recombinant human collagen type III microgel: an advanced injectable dermal filler for rejuvenating aging skin.Regenerative biomaterials · 2025Article
- Gelatin/hyaluronic acid-basedRegenerative biomaterials · 2025Article
- Fabrication of collagen-based biomaterials for sports medicine application.Regenerative biomaterials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scar formation can be effectively prevented when the proportion of collagen type I (Col I)/type III (Col III) is reduced. Unlike Col III, recombinant human collagen type III chain (RHC III chain) does not possess a triple helical structure. This study aimed to elucidate the capacity of fibroblasts to uptake RHC III chain, reduce the Col I/Col III ratio and determine its effects on wound healing and scar. RHC III chain demonstrates qualified cell compatibility. In cell experiments, immunofluorescence and western blot (WB) analyses revealed an increase in the polyhistidine tag level, indicating that RHC III chain in internalized by these cells. Transmission electron microscopy showed increased intracellular phagocytic activity, indicating that RHC III chain enters fibroblasts by endocytosis. The immunofluorescence and WB showed that Col III synthesis enhanced, and Col I/Col III ratio reduced. However, the polyhistidine tag disappeared with time, indicating that RHC III chain degraded within cells and then synthesized into Col III. The content of newly synthesized Col III increases, but real-time fluorescence quantitative showed a decrease in Col III related gene content suggests the formation of negative feedback. However, due to the sufficient raw materials, the amount of Col III synthesis is still increasing, leading to the reduction of the ratio of type I collagen/type III collagen, which beneficial to wound healing and reduce scar hyperplasia. In animal experiments, the SD rat full-thickness skin defect model of wound suggests that RHC III chain also takes effect through endocytosis and ultimately promotes wound healing. The rabbit ear scar model suggests that RHC III chain inhibits scar proliferation by reducing the ratio of Col I/Col III. In summary, RHC III chain was endocytosed by fibroblasts to promote native Col III synthesis, as well as promote wound healing and reduce scar hyperplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.